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Abstract
Purpose
Advanced forms of prostate cancer (PCa) radiotherapy with either external beam therapy or
brachytherapy delivery techniques aim for a focal boost and thus require accurate lesion
localization and lesion segmentation for subsequent treatment planning. This study pro-
spectively evaluated dynamic contrast-enhanced computed tomography (DCE-CT) for the
detection of prostate cancer lesions in the peripheral zone (PZ) using qualitative and quanti-
tative image analysis compared to multiparametric magnet resonance imaging (mpMRI) of
the prostate.
Methods
With local ethics committee approval, 14 patients (mean age, 67 years; range, 57–78 years;
PSA, mean 8.1 ng/ml; range, 3.5–26.0) underwent DCE-CT, as well as mpMRI of the pros-
tate, including standard T2, diffusion-weighted imaging (DWI), and DCE-MRI sequences fol-
lowed by transrectal in-bore MRI-guided prostate biopsy. Maximum intensity projections
(MIP) and DCE-CT perfusion parameters (CTP) were compared between healthy and
malignant tissue. Two radiologists independently rated image quality and the tumor lesion
delineation quality of PCa using a five-point ordinal scale. MIP and CTP were compared
using visual grading characteristics (VGC) and receiver operating characteristics (ROC)/
area under the curve (AUC) analysis.
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Results
The PCa detection rate ranged between 57 to 79% for the two readers for DCE-CT and was
92% for DCE-MRI. DCE-CT perfusion parameters in PCa tissue in the PZ were significantly
different compared to regular prostate tissue and benign lesions. Image quality and lesion
visibility were comparable between DCE-CT and DCE-MRI (VGC: AUC 0.612 and 0.651,
p>0.05).
Conclusion
Our preliminary results suggest that it is feasible to use DCE-CT for identification and visual-
ization, and subsequent segmentation for focal radiotherapy approaches to PCa.
Introduction
Radiotherapy encompassing external beam intensity-modulated radiation therapy (IMRT)
and brachytherapy represent established treatment options for patients with localized prostate
cancer (PCa). In the current daily clinical routine, it is still recommended to include the whole
prostate in the clinical target volume for radiotherapy [1,2]. As local recurrences mainly occur
at the site of the primary tumor lesion [3], ongoing efforts are being made to establish a boost
focused on the tumor tissue, with a current standard dose for the remaining prostate [4].
Based on computerized treatment plan optimization algorithms and respective IMRT-based
dose delivery techniques, even multiple clinical target volumes (CTV) with different dose pre-
scriptions can be treated within one treatment session, and, at the same time, reducing the
dose to organs at risk (OAR) [5–8].
However, one of the prerequisites for focal radiotherapy techniques is to visualize, localize,
and segment the lesion for such focal therapy techniques. Verification of the correct position
of the CTV and OAR on a daily basis during treatment is an issue of ongoing research and
development in image-guided radiation therapy (IGRT) [9,10].
For the best delineation of these target volumes, multiparametric magnetic resonance imag-
ing (mpMRI) represents the clinical gold standard. The annotated mpMRI maps are subse-
quently registered with computed tomography (CT) images for IGRT planning. In the clinical
routine, this requires MR accessibility, which might not be available for all radiotherapy
departments. However, CT scanners are standard imaging workhorses available in almost all
radiotherapy departments.
Standard contrast-enhanced CT is, thus far, not able to visualize PCa sufficiently for com-
puterized treatment plan optimization for focal PCa radiotherapy. To overcome this limita-
tion, dynamic contrast-enhanced (DCE)-CT, which provides quantitative and qualitative
information about the vascularization of the prostate, seems to improve the applicability of CT
based on the initial feasibility studies [11–14]. The latest generation of CT scanners can pro-
vide DCE-CT examinations that offer high spatial and contrast resolution in combination with
a moderate radiation dose. These scanners might facilitate the use of DCE-CT for the evalua-
tion of prostate cancer and for microboost planning in patients in whom mpMRI is not
possible.
Therefore, the aim of this study was to prospectively evaluate dynamic DCE-CT for the
detection of PCa lesions using qualitative and quantitative image analysis compared to
mpMRI of the prostate.
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Materials and methods
Patients
This prospective study was approved by the ethical committee of the Medical University of
Vienna (Nr. 1789/2015) and in accordance with the Declaration of Helsinki. From December
2015 to May 2018, consecutive patients without contraindications to MRI or CT of the prostate
gland were eligible for this study. A priori exclusion criteria were CT contrast media allergic
reaction history and renal insufficiency. All patients gave their written, informed consent prior
to imaging.
All patients received an mpMRI within a three-month time window of the dynamic
DCE-CT examination. Only patients with an MRI-proven suspicious lesion (�PI-RADS 3) in
the peripheral zone (PZ) who were scheduled for MRI-guided transrectal biopsy were further
included in this study. Patients with a history of prostate therapy (e.g., brachytherapy) or ther-
apy to other organs in the vicinity of the prostate, or hormonal therapy, were excluded.
The study cohort included 14 patients with PCa in the PZ. The mean age was 67 years
(range from 57 to 78 years) and the mean PSA was 8.1 ng/ml 40 (range from 3.5 to 26.0 ng/
ml). Patient characteristics are given in Table 1.
MRI
The mpMRI examinations were performed using a vendor-supplied, combined spine array
coil and a body array receive-only coil on a 3T MRI system (Tim Trio, Siemens Healthineers,
Erlangen, Germany). To avoid deformation of the prostate, no endorectal coil was used. The
examination was performed in a feet-first supine position. To keep the level of peristaltic arte-
facts low, an anti-peristaltic agent (10mg hyoscine butyl-bromide, Buscopan1, Boehringer
Ingelheim GmbH, Germany) was injected.
Patients underwent the following MP-MRI protocol:
• Anatomical T2w turbo spin echo in all three planes (field of view [FOV] 200mm; 20 slices at
3.0.mm; matrix 320).
• Axial echo planar imaging DWI sequence (Spectrally adiabatic inversion recovery [SPAIR]
fatsat; matrix and FOV, 160 and 260 mm, respectively; slice thickness, 3.6 mm; 4 b-values [0,
100, 400, and 800 s/mm2];). Apparent diffusion coefficient maps (monoexponential
Table 1. Patient characteristics.
Parameter Value
No. of patients 14
Mean age (y) 67 (57–78)
Mean PSA level (ng/mL) 8.1 (3.5–26)
Mean lesion diameter on MRI images (mm) 11 (7–24)
PI-RADS
IV 11 (79%)
V 3 (21%)
Gleason score
3+3 3 (21%)
3+4 6 (43%)
4+5 5 (36%)
PSA, prostate-specific antigen; PI-RADS, Prostate Imaging Reporting and Data System
https://doi.org/10.1371/journal.pone.0225673.t001
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calculation) were automatically constructed by the scanner software using DWI images of all
b-values. In addition, high b-value images of 1400 s/mm2 were calculated as suggested in
PI-RADS v2 [15].
• Contrast-enhanced (DCE) MRI was acquired using a view-sharing, three-dimensional,
T1-weighted gradient echo sequence (TWIST) (70 repetitions; TWIST k-space subsampling
with central region A 30% and sampling density 25%, resulting in a temporal resolution of
4.22 sec; FOV 260 mm; matrix 160). Gadoterate-meglumine (Gd-DOTA, Dotarem1, Guer-
bet, France) was injected intravenously after three baseline-scans as a bolus (0.2ml/kg body
weight), using a power injector at a flow rate of 4ml/s, followed by a flush of 20ml of saline
solution.
Standard of reference
All lesions were verified by target-MRI in-bore biopsy, which was performed on a 1.5T MR
unit (Magnetom Avanto fit, Siemens Healthineers, Erlangen, Germany) as described previ-
ously [16]. One radiologist with six years of experience performed the transrectal biopsy. Per
lesion, at least three-to-five biopsy cores were obtained. A specialized urogenital pathologist
analyzed the biopsy specimens according to recent guidelines [17].
DCE-CT imaging protocol
CT examinations were performed on a 2 × 192-slice, dual-source CT system (Somatom Force,
Siemens Healthineers, Erlangen, Germany). The DCE-CT was planned based on the a priori
performed non-contrast pelvis CT with the following acquisition protocol: Active automatic
tube current modulation (CARE Dose 4D; Siemens Healthineers Forchheim, Germany); 120
mAs reference tube current; 0.5 s rotation time; pitch 0.6; 192 × 0.6 mm detector collimation.
After delineation of the prostate in the non-contrast scan, DCE-CT was performed using the
following acquisition protocol: Depending on patient’s body weight, tube voltage was set to 80
or 90 kVp, rotation time was 0.25 s, and slice collimation 48 × 1.2 mm, with a slice width of 5
mm. The scan length was set to 114 mm. The perfusion scan consisted of 26 scans within a
window of 47 seconds. The first 20 examinations were obtained at 1.5-second intervals, the
next six at three-second intervals. The increase in intervals was selected to reduce the radiation
exposure after the arterial influx. For the DCE-CT, all patients received an i.v. injection of a
70-mL bolus of nonionic iodinated contrast agent (5.0 mL/sec, Iomeron 400, Bracco Imaging,
S.p.A., Milan, Italy) followed by a saline chaser of 40 mL at 5mL/sec using an automatic dou-
ble-head injector. Patients were allowed to breathe normally during the perfusion examina-
tion. For the non-contrast scan, image reconstruction was performed using advanced modeled
iterative reconstruction (ADMIRE, Siemens Healthineers, Erlangen, Germany) software at an
IR strength level 3, which represents a standard level setting for non-contrast CT at our institu-
tion. DCE-CTs were post-processed on a SyngoVia workstation (syngo.via, version B20A; Sie-
mens Healthineers; Forchheim; Germany) using the “Perfusion” application and the “Tumor”
protocol with default settings. The software automatically generated a smoothed arterial time-
enhancement curve and colorimetric maps of blood volume (BV), blood flow (BF), flow
extraction production (FEP), and mean transit time (MTT), with each pixel representing a
parameter value. Reconstructed images were imported into the local picture archiving and
communication system. Dose-length-product (DLP) of the DCE-CT examinations and of the
total CT examination consisting of the non-contrast pelvic CT scan and the DCE-CT scan
were assessed.
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Subjective image quality of perfusion CT images
Two radiologists (Reader 1 = O1; Reader 2 = O2) (with four and six years of MRI and CT expe-
rience, respectively) blinded to the clinical history of the patients, independently assessed CT
images with at least 14 days between the readings.
Overall image quality
A score based on a LIKERT Scale ranging from 1 to 5 was used to describe the overall image
quality of DCE-CT images:
1 = images non-diagnostic;
2 = images poor but still interpretable;
3 = image quality acceptable;
4 = image quality good;
5 = image quality excellent.
Lesion visibility
Prostate lesions were subjected to qualitative analysis using visual grading analysis. The readers
evaluated how accurately lesions could be delineated and assigned a confidence score ranging
from 1–5. In patients with more than one lesion, an index lesion was assessed. The index lesion
was determined as the largest and best-visible lesion. The ordinal score was defined as:
1 = non-diagnostic,
2 = poor but still interpretable,
3 = acceptable,
4 = good,
5 = excellent.
Examples of image quality and lesion visibility are provided in Fig 1 and Fig 2.
Objective tumor perfusion parameter analysis
Quantitative image analyses were performed once by Reader 1. The volume of interest (VOI)
covering the whole tumor was drawn on the maximum intensity projection (MIP) DCE-CT
images. The MR images were used to identify the correct tumor location. Control VOIs were
placed on the contralateral side in suspected healthy tissue. For every VOI, a mean enhance-
ment curve was calculated and analyzed in the SyngoVia workflow.
Statistical analysis
Comparisons between CT perfusion parameters within a patient were tested by a paired t-test.
Ordinal visual analysis ratings were analyzed by visual grading characteristic (VGC) analysis, a
non-parametric, rank-invariant statistical method derived from receiver operating characteris-
tics (ROC) analysis, with the imaging method used as the classification and the visual grading
used as the predictor variable [18]. VGC was used to evaluate the difference in image quality
between the MIP reconstruction and CTP images. The area under the VGC curve (AUC) was
deemed to be a measurement of the difference in image quality when comparing two or more
4D perfusion CT of prostate cancer
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Fig 1. Examples of lesion delineation and image quality. Images were obtained in a 78-year-old, biopsy-naive man. DWI images
(A), 2D T2w images (B), dynamic contrast-enhanced MRI (C), pseudocolor maps (D), CT-MIP images (E), and CT images with
blood flow overlay (F), in the axial plane are shown. In the pseudocolor map, tissue is colored according to its contrast uptake over
time. Green areas represent a continuous uptake over time. Orange areas represent tissue that shows a plateau phase, and red areas
represent tissue with a washout. A lesion was detected in the left peripheral zone (arrow). For lesion delineation and image quality,
the score was excellent. Histopathology obtained by MRI-guided biopsy confirmed a PCa Gleason score 7 (3+4).
https://doi.org/10.1371/journal.pone.0225673.g001
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Fig 2. Examples of lesion delineation and image quality. Images were obtained in a 63-year-old, biopsy-naive man. DWI images (A), 2D
T2w images (B), dynamic contrast-enhanced MRI (C), pseudocolor maps (D), CT-MIP images (E), and CT images with blood flow overlay
(F), in the axial plane are shown. In the pseudocolor map, tissue is colored according to its contrast uptake over time. Green areas represent a
continuous uptake over time. Orange areas represent tissue that shows a plateau phase, and red areas represent tissue with a washout. A
lesion was detected in the right peripheral zone (arrow). For lesion delineation and image quality, the score was acceptable. Histopathology
obtained by MRI-guided biopsy confirmed a PCa Gleason score 7 (4+3).
https://doi.org/10.1371/journal.pone.0225673.g002
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modalities. The range value for the AUC is 0.5–1.0, whereas an AUC of 0.5 represents no supe-
riority of a method with regard to the rated image quality criterion, and a value of 0 or 1.0 rep-
resents absolute inferiority or superiority of the respective method with regard to the evaluated
image quality method. ROC analysis was used to compare the diagnostic performance of
tumor delineation using MIP and CTP images.
All statistical analysis was performed using SPSS 24.0 (IBM Corp., Armonk, NY, USA).
Intra-class correlation coefficient (ICC) estimates and their 95% confident intervals were cal-
culated based on a mean-rating (k = 2), absolute-agreement, two-way mixed-effects model
[19].
Data are expressed as mean ± standard deviation or median and range. A two-sided p-value
<0.05 was considered significant.
Results
Prostate cancer detection rate
Cancer detection rates for the readers were 57% and 78% for DCE-CT and 92% for both read-
ers for DCE-MRI. There were no significant differences in the DCE-CT detection rate between
Gleason scores.
Objective image parameters
Patients with PC showed significantly elevated DCE-CT perfusion parameters compared to
regular prostate tissue (Table 2). In addition, a time-curve analysis showed an increased rapid
uptake of the contrast agent in PCa in the PZ compared to regular prostate tissue both on the
DCE-CT and DCE-MRI (Fig 3, p<0.001).
Subjective image parameters and lesion visibility
Of the 14 PCa patients, the median (range) lesion visibility scores from both readers were 3
(1–5) and 2.5 (1–5) for MIP reconstructions and CTP images, respectively. Examples of excel-
lent or acceptable lesion delineation examinations are shown in Fig 1 and Fig 2. The median
(range) image quality scores were 5 (3–5) for the MIP reconstructions and 4.5 (3–5) for the
CTP images.
Visual grading characteristics analysis
For R1, the area under the VGC curve was significantly better for DCE-MRI compared to
DCE-CT: R1: 0.53 (0.36–0.70), p = 0.01, while the VGC was not significantly different for R2:
0.73 (0.55–0.91), p = 0.44 (Fig 4A). The area under the VGC did not differ between DCE-CT
and DCE-MRI reconstructions in terms of image quality: R1 0.53 (0.36–0.7), p = 0.72; R2 0.63
Table 2. DCE-CT perfusion parameters.
MIP BF BV MTT FEP
Tumor 116.8 ± 22.8��� 48.4 ± 23.7��� 5.6 ± 5.6��� 5.3 ± 1.5�� 25.4 ± 14.5���
Regular 84.2 ± 16.4 21.6 ± 5.4 1.9 ± 1.7 4.2 ± 0.8 12.6 ± 5.9
MIP maximum intensity projection (HU), BF blood flow (mL/min/100g), BV blood volume (mL/100 mg), MTT mean transit time (seconds), FEP flow extraction
product (mL/min/100g)
�p<0.05
��p<0.01
���p<0.001
https://doi.org/10.1371/journal.pone.0225673.t002
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(0.47–0.78), p = 0.1. (Fig 4B). The area under the VGC curve did not differ between DCE-CT
MIP reconstructions and CT color maps in terms of lesion visibility—R1 0.53 (0.31–0.73),
p = 0.83; R2 0.52 (0.31–0.74), p = 0.85 (Fig 4C)—or image quality—R1 0.58 (0.39–0.79),
p = 0.39; R2 0.51 (0.34–0.69), p = 0.91 (Fig 4D).
Inter-reader agreement
There was an excellent inter-reader agreement for lesion delineation for MIP reconstructions,
with an ICC 0.989 (0.964–0.996) and for CTP maps, with an ICC 0.988 (0.964–0.966) (for both
p<0.001). In addition, there was a good agreement for MIP image quality, with an ICC 0.953
(0.857–0.985) and for CTP image quality, with an ICC 0.802 (0.378–0.937).
Radiation dose
Mean DLP of the DCE study performed over the z-axis of the tumor was 1376.5 ± 168.1
mGy�cm, which corresponded to an effective dose of 23.4 ± 2.9 mSv, if using a conversion fac-
tor of 0.017 for the pelvis region [20]. Mean DLP of the total non-contrast pelvic CT was
153.9 ± 22.8 mGy�cm, which corresponded to an effective dose of 2.6 ± 0.4 mSv, resulting in
an mean DLP for the whole CT examination of 1530.5 ± 182.7 mGy�cm, which corresponded
to an effective dose of 26 ± 3.1 mSv.
Discussion
In the present study, we investigated the feasibility of DCE-CT for the identification and delin-
eation of target volumes in patients with PCa. We found that, in patients with PCa, DCE-CT
of the prostate allows accurate identification and delineation of target volumes in the PZ. In
particular, objective image parameters that included all lesions showed a significant difference
between malignant and regular prostate tissue.
In the clinical scenario of patients with histology-proven PCa who are scheduled for focal
boost therapy to the macroscopic tumor area, exact tumor structure/lesion delineation using a
clinically suitable method is of utmost importance for treatment planning [5,21,22]. The excel-
lent soft tissue contrast of MRI has been proven to accurately delineate PCa [23], while CT has
Fig 3. Average time curves of contrast uptake in PCa versus healthy regular prostate tissue. (A) Dynamic contrast-enhanced computed tomography
(DCE-CT) and (B) dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), depicted for tumors in the peripheral zone. HU, Hounsfield
Units.
https://doi.org/10.1371/journal.pone.0225673.g003
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been of limited value thus far in this respect. Due to technical improvements in CT hardware
and post processing software, there is growing evidence that suggests that CT is able to detect
abnormalities of the prostate gland. In a retrospectively collected series of pelvic CT in 27 PCa
patients, the overall agreement for tumor detection between mpMRI and single-phase CT was
85.2% [24]. In another retrospective study, Glazer et al. reevaluated non-dynamic, contrast-
enhanced CT of the abdomen and pelvis in 90 patients with PCa and 49 patients without PCa.
A visual grading score of 5 increased the likelihood of a higher-grade PCa from 31% to 81% in
this study population [25]. These two studies might suggest that, even in single phase pelvic
CT, a PCa lesion can be detected. However, as contrast material arrival and inflow in the pros-
tate gland varies depending on physiological conditions, such as heart rate and cardiac ejection
volume, a dynamic acquisition might provide a more precise evaluation of healthy and malig-
nant prostate tissue. The tumor detection rate using DCE-CT in our study ranged between
Fig 4. Visual grading characteristic curves for lesion visibility (A, C) and image quality (B, D) assessment comparing DCE-CT and DCE-MRI (A, B) and
DCE-CT MIP and CTP (C, D) reconstructions. R2 scored DCE-MRI significantly better than DCE-CT in terms of lesion visibility (VGC 0.73, p = 0.01) (A). There
were no significant differences in terms of general image quality between DCE-CT and DCE-MRI (B). There was no significant difference between the different image
reconstructions with regard to lesion visibility and image quality (p>0.05) (C, D). R, reader; VGC, visual grading characteristics; DCE-CT, dynamic contrast-enhanced
computed tomography; DCE-MRI, dynamic contrast-enhanced magnet resonance imaging; MIP, maximum intensity projections; CTP, computed tomography
perfusion parameters.
https://doi.org/10.1371/journal.pone.0225673.g004
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57% to 78%, and, therefore, was inferior to the referenced study above with 85.2%. These dif-
ferences are mainly due to the applied selection criteria in the current study where only
patients scheduled for MRI-guided prostate biopsy were included, with consequently smaller
lesions with a lower Gleason score, compared to the retrospective studies. The relatively high
difference in the detection rate between the two readers is most likely attributable to differ-
ences in experience level in assessing DCE-CT images. The agreement between readers, as well
as general performance, will increase as the training levels increase with this new technique.
Similar to Glazer et al. [25] and Jia et al. [24], we found that DCE-CT enables the detection
and differentiation of PCa in the PZ. A veritable advantage of DCE-CT compared to single-
phase CT is the ability to generate MIP images and perfusion maps. Whereas MIP images sim-
ply display the maximal attenuation obtained during the dynamic acquisition for each voxel,
perfusion maps represent quantitative biological parameters, including BF, BV, MTT, and
FEP.
As expected, PCa showed an early uptake of contrast agent, followed by a rapid wash-out,
compared to healthy tissue. Consequently, PCa were visualized as hyper-attenuating lesions on
MIP reconstruction with altered perfusion parameters compared to the benign prostate tissue,
which is in line with previous investigations [14,26–28]. Interestingly, subjective image param-
eters for lesion visualization were rated better for the MIP reconstructions compared to the
perfusion maps. In contrast to single-phase CT, the advantage of MIP reconstructions remains
that they seem to be independent of variances in contrast material arrival. This might be due
the fact that the maximum hyper-attenuating voxel is displayed, and thus, improves the visual-
ization of hyper-attenuating lesions.
DCE-CT might be of great value for patients with PCa in a focal radiotherapy setting who
are not suitable for MR due to contraindications, such as pacemakers, metal implants, or claus-
trophobia. DCE-CT might act as an alternative to MRI in these patients to localize the area of
macroscopic tumor tissue and use this information for accurate RT planning. DCE-CT may
also lead to reduced costs and time saved by not having to acquire an MRI. Although the radia-
tion dose of the DCE-CT of approximately 26 mSv was high in this study, further studies could
reduce this by lowering the number of scans and increasing the time gap between scans. How-
ever, the total added radiation dose is low compared to the dose delivered during radiotherapy
[29].
In addition to lesion detection and lesion segmentation, quantitative and other advanced
imaging methods have been explored for response assessment [2,30,31]. Although, at present,
most studies concerning lesion characterization for both segmentation and response assess-
ment focus on mpMRI, DCE-CT might also be of value in the response assessment and serve
as an imaging biomarker for these patients.
This study has several limitations that need to be discussed. First, the total number of
patients is low and only patients with PZ tumors were included. Second, as we included
patients with Gleason scores 6–9, we had a high number of patients with low-Gleason-score
tumors. Based on previous reports, in which higher-grade tumors were better visible on pelvic
CTs [14,25], it is likely that a higher number of high-grade tumors would have improved the
detection rate of CTs. In addition, we did not calculate the false-positive or false-negative rate.
We believe that our study design was not suited to accurately calculate these metrics, because
we included only patients with prostate carcinoma in the peripheral zone. Finally, we did not
include patients with gold markers/fiducials in place. These might reduce the DCE-CT image
quality.
4D perfusion CT of prostate cancer
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Conclusion
In conclusion, our preliminary results suggest that, in patients with PCa, DCE-CT allows iden-
tification and visualization of macroscopic tumor areas in the peripheral zone in up to approx-
imately 80 percent of patients. Further studies are needed to evaluate the potential of DCE-CT
as a non-invasive imaging biomarker for treatment response assessment.
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